medigraphic.com
ISSN 1527-3172 (Electronic)

2013, Number 4

<< Back Next >>

MEDICC Review 2013; 15 (4)

Aging and dementia: implications for Cuba’s research community, public health and society

Llibre RJJ

Language: English
References: 35
Page: 54-59
PDF size: 180.00 Kb.


ABSTRACT

Dementia is a syndrome that has great repercussions for quality of life of patients and their families, as well as a high social cost. A [2009] systematic review of research evidence and consensus of expert opinions showed that 36 million people live with dementia worldwide, with 4.6 million new cases every year (similar to the global incidence of nonfatal stroke). The prevalence of dementia in older Cubans is high, with rates ranging from 6.4% to 10.2%, or about 130,000 persons (1.1% of the total population). This number is expected to rise to 260,000 by 2030. The age-standardized annual incidence of dementia is also high: 21 per 1000 population, with 28,750 new cases annually. Dementia is the leading cause of disability among older adults and is the main cause of dependency, financial burden and caregiver stress.
In this review, we highlight the importance of epidemiological research to obtain greater knowledge of the disease, improve health services, promote actions for prevention and early diagnosis, and implement a national strategy to address dementia in the Cuban population, itself now immersed in two processes: accelerated demographic aging and epidemiologic transition.


REFERENCES

  1. Alzheimer A. Über eine eigenartige erkrankung der hirnrinde. Allg Z Psychiat. 1907;64:146–8. German.

  2. Prince M, Jackson J. Alzheimer’s Disease International. World Alzheimer Report 2009. Executive Summary. London: Azheimer’s Disease International; 2009. 24 p.

  3. Christensen K, Doblhammer G, Rau R. Ageing populations: the challenges ahead. Lancet. 2009;374:1196–1208.

  4. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746–53.

  5. Ministry of Public Health (CU). Statistical Yearbook, MINSAP, Cuba [Internet]. Havana: Ministry of Public Health (CU); 2009 [cited 2010 Aug 24]. Available from: http://fi les.sld.cu/dne/ fi les/2010/04/anuario-2009e3.pdf. Spanish.

  6. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–7.

  7. Llibre Rodríguez JJ, Ferri CP, Acosta D, Guerra M, Prince M. Prevalence of dementia in Latin America, India, and China: a population-based crosssectional survey. Lancet. 2008;372:464–74.

  8. Llibre Rodríguez JJ, Valhuerdi A, Sanchez II, Reyna C, Guerra MA, Copeland JRM, et al. The prevalence correlates and impact of dementia in Cuba. A 10/66 Group population-based survey. Neuroepidemiology. 2008;31:243–51.

  9. Llibre Rodríguez JJ. Demencias y enfermedad de Alzheimer en la población cubana. Havana: Editorial Científi co-Técnica; 2008. ISBN. 978-959- 05-0544-7. Spanish.

  10. Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodríguez JJ, et al. Dementia incidence and mortality in middle income countries, and associations with age, sex, socioeconomic position and indicators of cognitive reserve. A 10/66 Dementia Research Group population-based cohort study. Lancet. 2012 May 23. doi:10.1016/ S0140-6736(12)60399-7.

  11. The incid ence of dementia in Canada. The Canadian Study of Health and Aging working group 2000. Neurology. 2000 Jul 12;55(1):66–73.

  12. Matthews F , Brayne C; Medical Research Council Cognitive Function and Ageing Study Investigators 2005. The Incidence of Dementia in England and Wales: Findings from the Five Identical Sites of the MRC CFA Study. PLoS Med;2(8):e193.

  13. Sousa RM, Ferri CP, Acosta D, Albanese E, Llibre Rodríguez JJ, Prince M, et al. The contribution of chronic diseases to disability among older people in low and middle income countries. A 10/66 Dementia Research Group population-based survey. Lancet. 2009;374:1821–30.

  14. Alzheimer’s Disease International. World Alzheimer Report 2010. The Global Economic Impact of Dementia. London: Alzheimer’s Disease International; 2010

  15. Hughes T, Ganguli M. Modifi able Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. Curr Psychiatry Rev. 2009 May 1;5(2):73–92.

  16. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;(7):137–52.

  17. Kuh D, Ben-Shlomo Y, Lynch J, Hallqvist J, Power C. Life course epidemiology. J Epidemiol Community Health. 2003;57:778–83.

  18. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011;377:1019–31.

  19. Lee Y, Back JH, Kim J. Systematic review of health behavioural risks and cognitive health in older adults. Int Psychogeriatr. 2010;22:174–87.

  20. Grupo de trabajo de la Guía de Práctica Clínica sobre la atención integral a las personas con enfermedad de Alzheimer y otras demencias. Guía de Práctica Clínica sobre la atención integral a las personas con enfermedad de Alzheimer y otras demencias. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Guías de Práctica Clínica en el SNS: AIAQS Núm. 2009/07. Cataluña: Agència d’Informació, Avaluació i Qualitat en Salut de Cataluña; 2010. Spanish.

  21. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:387–403.

  22. Petersen RC. Mild Cognitive Impairment. N Engl J Med. 2011;364:2227–34.

  23. Farlow MR. Alzheimer’s disease. Continuum Lifelong Learning Neurol. 2007;13(2):39–68.

  24. Rodríguez Rivera L, Llibre Rodríguez JJ. Práctica médica en las demencias. Havana: Editorial Ciencias Médicas; 2010. ISBN 978-959-212-620- 6. Spanish.

  25. Llibre Guerra JC. Enfoque de un paciente con demencia en la atención primaria de salud. In: Demencias y enfermedad de Alzheimer en la población cubana. Havana: Editorial Científi co- Técnica; 2008. ISBN. 978-959-05-0544-7. Spanish.

  26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. Washington DC: AMA; 1994.

  27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–44.

  28. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Ageing and the Alzheimer’s Association workgroup. Alzheimer’s and Dementia. 2011; doi: 10.1016/j. jalz.2011.03.005.

  29. World Health Organization. Dementia: A public health priority [Internet]. Geneva: World Health Organization; 2012 [cited 2010 Aug 24]. 112 p. Available from: http://www.who.int/mental_health/ publications/dementia_report_2012.

  30. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819–28.

  31. Llibre Rodríguez JJ, Valhuerdi A, Calvo M, Guerra M. Dementia and Non-communicable diseases in Older Adults in Havana City and Matanzas Province, Cuba. MEDICC Rev. 2011 Oct;13(4):30–7.

  32. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; 1: CD005593.

  33. Reisberg B, Doody R, Stoffl er A. Memantine Study Group. Memantine in moderate-tosevere Alzheimer’s disease. N Engl J Med. 2003;348:1333–41.

  34. Brodaty H, Breteler M, DeKosky S, Dorenlot P. The World of Dementia Beyond 2020. J Am Geriatr Soc. 2011. doi: 10.1111/j.1532-5415.2011.

  35. Orrell M, Woods B. Should we use individual cognitive stimulation therapy to improve cognitive function in people with dementia? BMJ. 2012 Feb 15;344:e633. doi: 10.1136/bmj.e633.




2020     |     www.medigraphic.com